Graph Therapeutics
PrivateLast Round
Early Funding
Jun 22, 2026
Total Funding Raised
$8.1M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Graph Therapeutics operates in Healthcare & Life Sciences and is based in Vienna. Its latest recorded funding round was an Early Funding round in June 2026.
Graph Therapeutics is a biotechnology company developing an AI-powered platform for precision drug discovery in inflammation and immunology.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Graph Therapeutics Comparables
Compare Graph Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immunai | 77% | |
| Seismic | 77% | |
| Sightera Biosciences | 77% |
For institutional investors. Book with your work email.
Graph Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Jun 22, 2026 | ||||
| Pre Seed | Jan 9, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Graph Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NAVEC Investment Management | Pre Seed |
| Merantix Capital | Early Funding, Pre Seed |
| Daphni | Early Funding |
| SquareOne Venture Capital | Early Funding |
| NAVEC Investment Management | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 22, 2026
$5M round led by Daphni
- May 7, 2025
Grew 33% QoQ from 9 to 12 employees.
For institutional investors. Book with your work email.
Graph Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Graph Therapeutics's valuation, stock price, and market status.
Is Graph Therapeutics a public or private company?
Graph Therapeutics is a private company.
What is the current stock price of Graph Therapeutics?
Graph Therapeutics is a private company, so its shares have no public market price. Caplight tracks Graph Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Graph Therapeutics worth (valuation)?
Valuation information for Graph Therapeutics is not publicly available.
Can I buy Graph Therapeutics stock?
Graph Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Graph Therapeutics's last funding round?
Graph Therapeutics's most recent funding round was Early Funding on June 22, 2026.
Who are the main investors in Graph Therapeutics?
Key investors in Graph Therapeutics include Merantix Capital, Daphni.
Will Graph Therapeutics IPO soon?
No public IPO plans have been announced for Graph Therapeutics.
How can I track Graph Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Graph Therapeutics's shares on secondary markets.